biospecimen banks

WRNMMC UsToo! Newsletter

 

Current Newsletter - NOVEMBER 2014, Volume 23 Issue 4

After eleven years of the WRNMMC Prostate Cancer Newsletter distributed in hard copy via the US Postal Service, the newsletter is now completely "digital," and posted exclusively to the CPDR web site.

The WRNMMC US TOO Newsletter started as an eight page publication intended for the military prostate cancer community in the Greater Washington, D.C. metropolitan area. It grew rapidly under the leadership of the late Bob Zveare, the founding editor. Initially printed in 200 copies for local distribution, it is now digitally distributed far beyond "the Beltway."

The Newsletter is produced and distributed quarterly without charge to the expanded readership. Corporate grants and individual donations from the readership provide the financial wherewithal to sustain the operation. There are no paid employees. Instead, the Newsletter relies on volunteer effort from within the WRNMMC US TOO board of directors for its operation. The respective staffs of the WRNMMC Urology Service and the Department of Defense Center for Prostate Disease Research (CPDR) also provide support and encouragement.

 

Newsletter Archive

Index of Past Issues

August 2014, Volume 23 Issue 3

May 2014, Volume 23 Issue 2

February 2014, Volume 23 Issue 1

November 2013, Volume 22 Issue 4

August 2013, Volume 22 Issue 3

May 2013, Volume 22 Issue 2

February 2013, Volume 22 Issue 1

November 2012, Volume 21 Issue 4

August 2012, Volume 21 Issue 3

May 2012, Volume 21 Issue 2

February 2012, Volume 21 Issue 1

November 2011, Volume 20 Issue 3

August 2011, Volume 20 Issue 2

May 2011, Volume 20 Issue 1

August 2010, Volume 19 Issue 2

February 2010, Volume 19 Issue 1

November 2009, Volume 18 Issue 4<br>

August 2009, Volume 18 Issue 3

May 2009, Volume 18 Issue 2

February 2009, Volume 18 Issue 1

November 2008, Volume 17 Issue 4

August 2008, Volume 17 Issue 3

May 2008, Volume 17 Issue 2

February 2008, Volume 17 Issue 1

November 2007, Volume 16 Issue 4

August 2007, Volume 16 Issue 3

May 2007, Volume 16 Issue 2

February 2007, Volume 16 Issue 1

November 2006, Volume 15 Issue 4

August 2006, Volume 15 Issue 3

May 2006, Volume 15 Issue 2

February 2006, Volume 15 Issue 1

November 2005, Volume 14 Issue 4

August 2005, Volume 14 Issue 3

May 2005, Volume 14 Issue 2

February 2005, Volume 14 Issue 1

November 2004, Volume 13 Issue 4

August 2004, Volume 13 Issue 3

May 2004, Volume 13 Issue 2

February 2004, Volume 13 Issue 1

November 2003, Volume 12 Issue 4

August 2003, Volume 12 Issue 3

 

 

CURRENT EVENTS


September 29, 2014

Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients

REDWOOD CITY, CA – Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with the Uniformed Services University of the Health Sciences' (USU) Center for Prostate Disease Research (CPDR) supported by a multi-disciplinary team of investigators under a cooperative research and development agreement with USU. This new large study reconfirmed the biopsy-based test's Genomic Prostate Score (GPS) as a predictor of adverse pathology at surgery and, for the first time, validated GPS as a strong independent predictor of a rise in prostate-specific antigen (PSA) following surgery (biochemical recurrence).

Read Full Article.

Read Publication - European Urology

 

WRNMMC UsToo!

Read the NOVEMEBR 2014 Newsletter